San Francisco, California 94143

  • Deficit Hyperactivity Disorder (ADHD)

Purpose:

The primary objective of this trial was to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective was to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.


Criteria:

Inclusion Criteria: 1. Aged 18-70 years 2. Female subjects of child-bearing potential must test negative to pregnancy and use appropriate birth control method from the beginning of study to the 15 days later after ending of study 3. Subjects must be able to understand and willing to sign informed consent 4. Able to discontinue the use of any psychotropic medications for the treatment of ADHD symptoms at screening 5. Meet strict operational criteria for adult ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) 6. A total score of 20 or higher on the 18-item total ADHD symptoms score of Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Self Report: Short Version (CAARS-S:S) at screening 7. Have a moderate or severe symptom of ADHD with score of 4 or higher in Clinical Global Impression-ADHD-Severity (CGI-ADHD-S) at screening Exclusion Criteria: 1. Have any clinically significant concurrent medical condition (endocrine, renal, respiratory, cardiovascular, hematological, immunological, cerebrovascular, neurological, anorexia, obesity or malignancy) that has become unstable and may interfere with the interpretation of safety and efficacy evaluations 2. Have any clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings at screening that, in the opinion of the investigator, may interfere with the interpretation of safety or efficacy evaluations 3. Have known serological evidence of human immunodeficiency virus (HIV) antibody 4. Are pregnant as confirmed by a positive pregnancy test at screening 5. Have QTc values >450 msec at screening using Fridericia's QTc formula 6. Have current of bipolar and psychotic disorders 7. Have a current major depression disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder and eating disorder (also if treated but not currently symptomatic) 8. Have any history of a significant suicide attempt, or possess a current risk of attempting suicide, in the investigator's opinion, based on clinical interview and responses provided on the Beck Scale for Suicidal Ideation (BSS) 9. Have a history of jailing or imprisonment in the past 6 months due to worsening of symptoms of ADHD


NCT ID:

NCT02699086


Primary Contact:

Study Director
Keith R McBurnett, PhD
University of California San Francisco, School of Medicine

Hsien-Ming Wu, MS
Phone: 886-3-657-9631
Email: sonnywu@bioliteinc.com


Backup Contact:

N/A


Location Contact:

San Francisco, California 94143
United States

Keith R McBurnett, PhD
Phone: 415-476-7892
Email: Keith.McBurnett@ucsf.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 02, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.